XTX Topco Ltd Increases Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

XTX Topco Ltd lifted its position in Fresenius Medical Care AG (NYSE:FMS) by 70.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,769 shares of the company’s stock after buying an additional 16,487 shares during the quarter. XTX Topco Ltd’s holdings in Fresenius Medical Care were worth $847,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. National Bank of Canada FI increased its position in shares of Fresenius Medical Care by 17.4% in the third quarter. National Bank of Canada FI now owns 23,270 shares of the company’s stock worth $496,000 after purchasing an additional 3,451 shares during the last quarter. Virtus Investment Advisers Inc. bought a new position in shares of Fresenius Medical Care in the third quarter worth approximately $226,000. Quantinno Capital Management LP increased its position in shares of Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of Fresenius Medical Care in the third quarter worth approximately $237,000. Finally, Glenmede Trust Co. NA bought a new position in Fresenius Medical Care during the third quarter valued at approximately $271,000. 8.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on FMS shares. Truist Financial raised their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Berenberg Bank assumed coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective for the company. Finally, StockNews.com assumed coverage on Fresenius Medical Care in a research note on Thursday, November 28th. They set a “strong-buy” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Fresenius Medical Care currently has an average rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Stock Down 0.4 %

NYSE FMS opened at $23.91 on Wednesday. The stock has a market cap of $14.03 billion, a PE ratio of 19.76, a P/E/G ratio of 0.98 and a beta of 0.93. Fresenius Medical Care AG has a 12 month low of $17.93 and a 12 month high of $24.31. The stock’s 50 day moving average is $21.29 and its 200 day moving average is $20.39. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.